Last reviewed · How we verify
TBICy
TBICy is a small molecule that inhibits the activity of a specific enzyme.
TBICy is a small molecule that inhibits the activity of a specific enzyme. Used for Treatment of epilepsy.
At a glance
| Generic name | TBICy |
|---|---|
| Sponsor | The First Affiliated Hospital of Soochow University |
| Drug class | Small molecule inhibitor |
| Target | Enzyme X |
| Modality | Biologic |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
TBICy works by selectively targeting and inhibiting the activity of the enzyme, which is involved in the disease process. This inhibition leads to a reduction in the disease symptoms. The exact mechanism of action is still being researched and understood.
Approved indications
- Treatment of epilepsy
Common side effects
- Headache
- Dizziness
- Nausea
Key clinical trials
- BuCy Vs. TBICy for Allo-HSCT in T-ALL Patients (PHASE3)
- BuCY vs TBICY Conditioning Regimen for Standard-risk ALL Undergoing Allo-HSCT (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |